Impact of Non-Alcoholic Fatty Liver Disease Severity on the Incidence of Major Adverse Cardiovascular Events: A Meta-Analysis of Longitudinal Cohort Studies
DOI:
https://doi.org/10.70749/ijbr.v3i4.996Keywords:
Non-alcoholic Fatty Liver Disease, NAFLD, MACE, Cardiovascular Risk, Liver Fat Severity, Meta-analysisAbstract
Background: Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized not only as a hepatic disorder but also as a significant contributor to cardiovascular morbidity. The association between NAFLD severity and the risk of major adverse cardiovascular events (MACE) remains inadequately defined, especially across diverse populations and diagnostic approaches. Objective: To evaluate the impact of NAFLD severity on the incidence of MACE by synthesizing evidence from longitudinal cohort studies. Methods: A systematic literature search was conducted across PubMed, Embase, Web of Science, and the Cochrane Library, identifying longitudinal cohort studies that assessed the relationship between NAFLD severity and MACE outcomes. Studies were selected based on predefined inclusion criteria, and data were extracted independently by two reviewers. Risk ratios (RR) with 95% confidence intervals (Cis) were pooled using a random-effects model. Heterogeneity and publication bias were assessed via the I² statistic and funnel plots, respectively. Results: Three studies with a combined sample of over 136,000 participants were included. Subgroup analysis comparing severe vs. Mild NAFLD showed a non-significant increased risk of MACE (RR: 1.50; 95% CI: 0.97–2.32). When comparing NAFLD to non-NAFLD populations, the pooled RR was 1.19 (95% CI: 0.80–1.79). Overall, the total pooled estimate across all studies indicated a non-significant association between NAFLD severity and MACE (RR: 1.26; 95% CI: 0.92–1.73), with substantial heterogeneity (I² = 88%). Conclusion: Although not statistically significant, the findings suggest a trend toward increased cardiovascular risk with greater NAFLD severity. The results highlight the need for standardized diagnostic criteria and further high-quality longitudinal research to clarify this relationship and inform cardiovascular risk stratification in NAFLD patients.
Downloads
References
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2017). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328–357. https://doi.org/10.1002/hep.29367
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Askling, J., Hultcrantz, R., & Kechagias, S. (2018). Cardiovascular risk factors in non‐alcoholic fatty liver disease. Liver International, 39(1), 197–204. https://doi.org/10.1111/liv.13973
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016c). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology, 65(3), 589–600. https://doi.org/10.1016/j.jhep.2016.05.013
Targher, G., Day, C. P., & Bonora, E. (2010). Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 363(14), 1341–1350. https://doi.org/10.1056/nejmra0912063
Vaz, K., Kemp, W., Majeed, A., Lubel, J., Magliano, D. J., Glenister, K. M., Bourke, L., Simmons, D., & Roberts, S. K. (2024b). NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia. Hepatology International, 18(4), 1135–1143. https://doi.org/10.1007/s12072-024-10706-1
Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., & Zhang, Z. (2016). Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Scientific Reports, 6(1). https://doi.org/10.1038/srep33386
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2015). Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84. https://doi.org/10.1002/hep.28431
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016b). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology, 65(3), 589–600. https://doi.org/10.1016/j.jhep.2016.05.013
Wong, V. W., Wong, G. L., Yip, G. W., Lo, A. O., Limquiaco, J., Chu, W. C., Chim, A. M., Yu, C., Yu, J., Chan, F. K., Sung, J. J., & Chan, H. L. (2011). Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut, 60(12), 1721–1727. https://doi.org/10.1136/gut.2011.242016
Wu, W., Ma, W., Yuan, S., Feng, A., Li, L., Zheng, H., Li, S., He, N., Huang, Y., & Lyu, J. (2023). Associations of unhealthy lifestyle and nonalcoholic fatty liver disease with cardiovascular healthy outcomes. Journal of the American Heart Association, 12(23). https://doi.org/10.1161/jaha.123.031440
Vaz, K., Kemp, W., Majeed, A., Lubel, J., Magliano, D. J., Glenister, K. M., Bourke, L., Simmons, D., & Roberts, S. K. (2024). NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia. Hepatology International, 18(4), 1135–1143. https://doi.org/10.1007/s12072-024-10706-1
Shi, R., Li, X., Sun, K., Liu, F., Kang, B., Wang, Y., Wang, Y., Zhu, B., Zhao, X., Liu, Z., & Wang, X. (2024). Association between severity of nonalcoholic fatty liver disease and major adverse cardiovascular events in patients assessed by coronary computed tomography angiography. BMC Cardiovascular Disorders, 24(1). https://doi.org/10.1186/s12872-024-03880-5
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
